Get started
Author

Z. John Zhong

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
2011 · Sandra V Navarra, Renato M Guzmán, et al. · The Lancet · 2,102
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
2011 · Richard Furie, Michelle Petri, et al. · Arthritis & Rheumatism · 1,717
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
2009 · Daniel J. Wallace, William Stohl, et al. · Arthritis Care & Research · 588
PDF
Novel evidence‐based systemic lupus erythematosus responder index
2009 · Richard A. Furie, Michelle A. Petri, et al. · Arthritis Care & Research · 490
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
2012 · William Stohl, Falk Hiepe, et al. · Arthritis & Rheumatism · 420
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
2012 · Susan Manzi, Jorge Sánchez-Guerrero, et al. · Annals of the Rheumatic Diseases · 411
PDF
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
2012 · Ronald F van Vollenhoven, Michelle A Petri, et al. · Annals of the Rheumatic Diseases · 411
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
2012 · MA Dooley, F Houssiau, et al. · Lupus · 267
PDF
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
2013 · Ellen M. Ginzler, Daniel J. Wallace, et al. · The Journal of Rheumatology · 182
PDF
Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials
2013 · Michelle A. Petri, Ronald F. van Vollenhoven, et al. · Arthritis & Rheumatism · 181
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
2013 · Vibeke Strand, Roger A Levy, et al. · Annals of the Rheumatic Diseases · 145
PDF
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
2012 · DJ Wallace, S Navarra, et al. · Lupus · 122
Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
2012 · Joan T. Merrill, Ellen M. Ginzler, et al. · Arthritis & Rheumatism · 120
Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
2013 · William Stohl, Joan T. Merrill, et al. · The Journal of Rheumatology · 101
PDF
Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial
2012 · W. WINN CHATHAM, DANIEL J. WALLACE, et al. · The Journal of Rheumatology · 94
PDF
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
2014 · Richard Furie, Michelle A Petri, et al. · Lupus Science & Medicine · 79
PDF
Covariate‐adjusted borrowing of historical control data in randomized clinical trials
2017 · Baoguang Han, Jia Zhan, et al. · Pharmaceutical Statistics · 50
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
2013 · Wendy W. Cai, Michele Fiscella, et al. · Clinical Pharmacology in Drug Development · 28
Matching design for augmenting the control arm of a randomized controlled trial using real-world data
2022 · Yingying Liu, Bo Lu, et al. · Journal of Biopharmaceutical Statistics · 13
SAT0195 Impact of mycophenolate mofetil and/or corticosteroid treatment on outcomes of belimumab treatment in SLE
2012 · M. Schneider, J. Buyon, et al. · Annals of the Rheumatic Diseases · 5
SAT0192 Post-hoc analysis to assess effect of belimumab in patients on mycophenolate mofetil with renal manifestations at baseline
2012 · F. Houssiau, M.A. Dooley, et al. · Annals of the Rheumatic Diseases · 1
SAT0188 Early clinical improvement in SLE patients treated with belimumab
2012 · A. Doria, J. Sanchez-Guerrero, et al. · Annals of the Rheumatic Diseases · 1
A Reconfigurable Self-Clamp CSCR Converter With Fast-Converging MPPT for Energy Harvesting
2026 · Ziyang Zhong, Sijun Du, et al. · IEEE Journal of Solid-State Circuits
Reply
2013 · Michelle A. Petri, Ronald F. van Vollenhoven, et al. · Arthritis & Rheumatology
SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks
2012 · M. Petri, R.F. van Vollenhoven, et al. · Annals of the Rheumatic Diseases
Works count: 30
Citation count: 7,528
H-index: 18
I10-index: 19
Year
Topic
Type